Study of Vitamin D and Effect on Heart Disease and Insulin Resistance

NCT ID: NCT01093417

Last Updated: 2016-07-14

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-01-31

Study Completion Date

2010-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate how Vitamin D affects endothelial function, inflammation, lipids, insulin resistance, vitamin D levels, and parathyroid hormone (PTH).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Randomized placebo controlled trial of vitamin D supplementation in HIV infected subjects with vitamin D deficiency

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Human Immunodeficiency Virus (HIV) Vitamin D Deficiency HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Participants that have been randomized into this arm will receive placebo pills.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Placebo pills will be administered to enrollees in this arm

Vitamin D 4000 IU

Participants that have been randomized into this arm will receive Vitamin D 4000 IU (International Units) daily.

Group Type ACTIVE_COMPARATOR

Vitamin D

Intervention Type DRUG

Vitamin D 4000 IU will be administered to enrollees on the active comparator arm

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vitamin D

Vitamin D 4000 IU will be administered to enrollees on the active comparator arm

Intervention Type DRUG

Placebo

Placebo pills will be administered to enrollees in this arm

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Calciferol

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HIV infected
* HIV-RNA \< 400 copies/ml at study entry and for 12 wks. prior
* 25-hydroxyvitamin D level \<20
* On a stable anti-retroviral (ARV) regimen for at least 12 weeks prior to study entry

Exclusion Criteria

* Pregnancy or Breast Feeding
* Diabetes
* Creatinine Clearance \<50
* Any active infectious or inflammatory condition
* aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>2.5 within 6 months prior to study entry
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospitals Cleveland Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Grace McComsey

Chief, Peds ID, Rheumatology and Global Health

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospitals of Cleveland Case Medical Center

Cleveland, Ohio, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Longenecker CT, Hileman CO, Carman TL, Ross AC, Seydafkan S, Brown TT, Labbato DE, Storer N, Tangpricha V, McComsey GA. Vitamin D supplementation and endothelial function in vitamin D deficient HIV-infected patients: a randomized placebo-controlled trial. Antivir Ther. 2012;17(4):613-21. doi: 10.3851/IMP1983. Epub 2011 Nov 17.

Reference Type DERIVED
PMID: 22293363 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

11-09-30

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Vitamin D Dose Finding Study
NCT01092338 COMPLETED PHASE2
Vitamin D HIV Study on Postmenopausal Women
NCT01375010 COMPLETED PHASE1/PHASE2
Vitamin D and Type 2 Diabetes Study
NCT01942694 COMPLETED NA
Effect of Vitamin D Treatment on Fatigue
NCT02022475 COMPLETED PHASE3